MUMBAI — Global brokerage firm Bernstein has launched coverage of six Indian pharmaceutical companies, identifying Zydus Lifesciences as its preferred investment pick, signaling renewed confidence in the country's healthcare manufacturing sector.
The brokerage's optimistic stance rests on three fundamental growth catalysts expected to reshape India's pharmaceutical landscape. Artificial intelligence-driven innovation is emerging as a primary force, enabling companies to accelerate drug discovery and streamline operational efficiency. Additionally, steady progress in specialized therapeutic segments promises differentiated revenue streams for domestic players.
Enhanced quality standards across manufacturing facilities represent the third critical driver, positioning Indian drugmakers to capture greater market share in regulated international markets, particularly the United States and Europe.
The positive outlook gains further support from current market valuations, which the brokerage views as compelling entry points for investors seeking exposure to India's pharmaceutical growth story.
India's pharmaceutical sector, which contributes approximately 1.7% to the national GDP, has emerged as a global generics powerhouse. The sector's expansion holds particular significance for Bihar, where pharmaceutical manufacturing investments have been gradually increasing, creating employment opportunities and contributing to the state's industrial diversification efforts.
The healthcare sector's robust fundamentals could attract sustained domestic and foreign institutional investment flows in coming quarters.